Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_3
2
50%
Ph phase_4
1
25%
Ph phase_2
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Other(1)

Detailed Status

Completed3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 32 (50.0%)
Phase 41 (25.0%)

Trials by Status

unknown125%
completed375%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_3

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

NCT05119855
completedphase_2

Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults

NCT05383560
unknownphase_3

Fourth COVID-19 Vaccine Dose- mRNA1273

NCT05230953
completedphase_4

Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients

NCT04885907

Clinical Trials (4)

Showing 4 of 4 trials
NCT05119855Phase 3

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Completed
NCT05383560Phase 2

Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults

Completed
NCT05230953Phase 3

Fourth COVID-19 Vaccine Dose- mRNA1273

Unknown
NCT04885907Phase 4

Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients

Completed

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4